GSTZ1 and hepatocellular carcinoma: HIF-1α inhibition combined with anti–programmed cell death ligand 1 (anti–PD-L1) therapy effectively prevented HCC growth in Gstz1-knockout mice, providing an alternative strategy for HCC treatment.